Novartis reports kidney function benefits for IgAN drug in phase III trial
Go back to Novartis reports kidney function benefits for IgAN drug in phase III trial| NOVARTIS AG (NYSE: NVS) | Delayed: 145.46 +1.89 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.57 | 52 Week High | $89.15 | |||
| Open | $144.57 | 52 Week Low | $69.84 | |||
| Day High | $145.51 | P/E | N/A | |||
| Day Low | $144.00 | EPS | $0.00 | |||
| Volume | 1,165,724 | |||||
